Bio + Health

Function Health Series B: Launching the Medical Intelligence Era

Daisy Wolf and Bryan Kim Posted November 19, 2025

We’ve all known someone whose life was altered by a diagnosis that came too late. We’ve felt that shock ourselves – that moment when you ask how something so serious could stay hidden for so long, despite good doctors, regular checkups, and doing everything “right.”

It stays with you.

And it’s what first drew us to Function: the belief that people shouldn’t be left guessing about their health until symptoms appear. The belief that the invisible should be visible. The belief that the future of healthcare should feel less like reacting to bad news, and more like understanding your body in real time.

From the beginning, Function was built with ferocious clarity: If we want people to live 100 healthy years, we need to give them access to all the data that matters – and the intelligence to understand it. Not someday. Now.

Today, we’re excited to share that a16z is investing in Function’s oversubscribed $298M Series B at a $2.5B valuation and that Function is launching a major milestone in their mission: the Medical Intelligence Lab.

Function started by redefining what routine health looks like. Its bi-annual, 100+ test lab panel gave hundreds of thousands of people a deeper, more comprehensive view of their biology than a traditional annual physical could offer. With the acquisition of Ezra, Function extended this visibility through accessible advanced MRI and CT imaging – making proactive scanning something everyone, not just the lucky few, could benefit from.

The launch of the Medical Intelligence Lab takes that vision further. Medical Intelligence unifies everything – labs, imaging, wearables, IoT signals, medical records, global research – into a continuously learning model designed to reveal early patterns, update insights as your body changes, and translate complexity into simple, meaningful action.

Finally, technology is achieving what we’ve always wanted healthcare to do: understand us deeply, anticipate issues early, and empower us to act.

At a16z, we look for companies building entirely new categories – not incrementally better tools. Function is building the intelligence layer for human health: the system we’ve long imagined but have never had. And in the process, it’s reshaping what proactive care can look like for billions of people.

To Jonathan and everyone at Function: congratulations on this milestone. The vision is bold, the execution relentless, and the mission – to help every person live 100 healthy years – could not be more important.

We’re honored to be building this new era of Medical Intelligence alongside you.

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Infra

new Investing in Deeptune

Marco Mascorro and Martin Casado
Growth

new Investing in Mind Robotics

Sarah Wang
Growth

Investing in Nexthop AI

Raghu Raghuram, Shangda Xu, and Guido Appenzeller
Fintech

Investing in Lio

Seema Amble, James da Costa, Eric Zhou, and Brian Roberts
Bio + Health

Investing in Ease

Daisy Wolf, Anish Acharya, and Eva Steinman

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.